Dr. Papadimitrakopoulou on Role of Immunotherapy in Lung Cancer

Vassiliki A. Papadimitrakopoulou, MD
Published: Friday, Feb 03, 2017



Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Patients with lung cancer who have a high expression of PD-L1—in more than 50% of cells—are found to benefit from PD-L1 monotherapy. It is not certain whether this is the best way to indicate eligibility for immunotherapy.

Although, with the recent approval of pembrolizumab (Keytruda), this subset of patients should also be considered for upfront immunotherapy, says Papadimitrakopoulou.
 


Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Patients with lung cancer who have a high expression of PD-L1—in more than 50% of cells—are found to benefit from PD-L1 monotherapy. It is not certain whether this is the best way to indicate eligibility for immunotherapy.

Although, with the recent approval of pembrolizumab (Keytruda), this subset of patients should also be considered for upfront immunotherapy, says Papadimitrakopoulou.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x